Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)
Completed
The Medicines Company
Phase 3
2003-12-01
The purpose of this study is to establish the efficacy of of clevidipine versus placebo in
treating postoperative hypertension. Approximately 100 patients with postoperative
hypertension undergoing coronary artery bypass grafting (CABG), off-pump coronary artery
bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or
valve replacement/repair procedures were anticipated to be randomly assigned to one of two
treatment groups: clevidipine or placebo.
Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)
Completed
The Medicines Company
Phase 3
2004-04-01
The purpose of this study is to establish the safety of clevidipine in the treatment of
perioperative hypertension. Approximately 500-900 patients with perioperative hypertension
undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or
minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve
replacement/repair procedures were anticipated to be randomly assigned to one of two
treatment groups: clevidipine or nitroglycerin.
Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)
Completed
The Medicines Company
Phase 3
2004-06-01
The purpose of this study is to establish the safety of clevidipine in the treatment of
perioperative hypertension. Approximately 250-500 patients with perioperative hypertension
undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or
minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve
replacement/repair procedures were anticipated to be randomly assigned to one of two
treatment groups: clevidipine or sodium nitroprusside.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
